{"id":"mecasermin-rinfabate","rwe":[{"pmid":"34717953","year":"2022","title":"Development of Protein-Specific Analytical Methodologies to Evaluate Compatibility of Recombinant Human (rh)IGF-1/rhIGFBP-3 with Intravenous Medications Co-Administered to Neonates.","finding":"","journal":"Journal of pharmaceutical sciences","studyType":"Clinical Study"},{"pmid":"25541285","year":"2015","title":"The insulin-like growth factor I system: physiological and pathophysiological implication in cardiovascular diseases associated with metabolic syndrome.","finding":"","journal":"Biochemical pharmacology","studyType":"Clinical Study"},{"pmid":"22952056","year":"2012","title":"Insulinlike growth factor (IGF)-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy.","finding":"","journal":"Molecular medicine (Cambridge, Mass.)","studyType":"Clinical Study"},{"pmid":"21225019","year":"2010","title":"Gateways to clinical trials.","finding":"","journal":"Methods and findings in experimental and clinical pharmacology","studyType":"Clinical Study"},{"pmid":"19627167","year":"2009","title":"Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.","finding":"","journal":"BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy","studyType":"Clinical Study"}],"tags":[{"label":"Biologic","category":"modality"},{"label":"H01AC05","category":"atc"},{"label":"Active","category":"status"},{"label":"Laron-type isolated somatotropin defect","category":"indication"},{"label":"Insmed","category":"company"},{"label":"Approved 2000s","category":"decade"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Insmed","patents":[{"type":"Biologic Exclusivity","filed":"December 12, 2005","source":"FDA Purple Book","status":"Active","expires":"December 12, 2012","territory":"US","patentNumber":"BLA 021884"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MECASERMIN RINFABATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:22:57.428389+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:22:57.428277+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:23:02.697631+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MECASERMIN RINFABATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:23:03.092841+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Insulin-like growth factor I receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:23:04.251328+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201717/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:23:03.794340+00:00"}},"allNames":["mecasermin rinfabate","mecasermin rinfabate recombinant"],"offLabel":[],"synonyms":["mecasermin rinfabate","mecasermin rinfabate recombinant"],"timeline":[{"date":"2005-12-12","type":"positive","source":"DrugCentral","milestone":"FDA approval (Insmed)"}],"approvals":[{"date":"2005-12-12","orphan":true,"company":"INSMED","regulator":"FDA"}],"ecosystem":[{"indication":"Laron-type isolated somatotropin defect","otherDrugs":[{"name":"mecasermin","slug":"mecasermin","company":"Ipsen Inc"}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","modality":"Biologic","explanation":"","oneSentence":"","technicalDetail":"MECASERMIN RINFABATE is a growth hormone receptor agonist that binds to the growth hormone receptor, triggering a cascade of intracellular signaling events that stimulate growth and development."},"commercial":{"launchDate":"2005","_launchSource":"DrugCentral (FDA 2005-12-12, INSMED)"},"purpleBook":{"bla":"021884","source":"FDA Purple Book","approvalDate":"December 12, 2005","licenseStatus":"Voluntarily Revoked","exclusivityExpiry":"December 12, 2012"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5197","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MECASERMIN%20RINFABATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MECASERMIN RINFABATE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://purplebooksearch.fda.gov/","fields":["biologicExclusivity"],"source":"FDA Purple Book"}],"_enrichedAt":"2026-03-30T12:31:20.043273","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:23:05.585871+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"somatropin","drugSlug":"somatropin","fdaApproval":"1976-07-30","relationship":"same-class"},{"drugName":"somatrem","drugSlug":"somatrem","fdaApproval":"1985-10-17","relationship":"same-class"},{"drugName":"mecasermin","drugSlug":"mecasermin","fdaApproval":"2005-08-30","relationship":"same-class"},{"drugName":"sermorelin","drugSlug":"sermorelin","fdaApproval":"1990-12-28","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"tesamorelin","drugSlug":"tesamorelin","fdaApproval":"2010-11-10","relationship":"same-class"},{"drugName":"somapacitan","drugSlug":"somapacitan","fdaApproval":"2020-08-28","relationship":"same-class"},{"drugName":"somatrogon","drugSlug":"somatrogon","fdaApproval":"2023-06-27","relationship":"same-class"},{"drugName":"lonapegsomatropin","drugSlug":"lonapegsomatropin","fdaApproval":"2021-08-25","relationship":"same-class"}],"genericName":"mecasermin rinfabate","indications":{"approved":[{"name":"Laron-type isolated somatotropin defect","source":"DrugCentral","snomedId":38196001,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"somatropin","brandName":"somatropin","genericName":"somatropin","approvalYear":"1976","relationship":"same-class"},{"drugId":"somatrem","brandName":"somatrem","genericName":"somatrem","approvalYear":"1985","relationship":"same-class"},{"drugId":"mecasermin","brandName":"mecasermin","genericName":"mecasermin","approvalYear":"2005","relationship":"same-class"},{"drugId":"sermorelin","brandName":"sermorelin","genericName":"sermorelin","approvalYear":"1990","relationship":"same-class"},{"drugId":"tesamorelin","brandName":"tesamorelin","genericName":"tesamorelin","approvalYear":"2010","relationship":"same-class"},{"drugId":"somapacitan","brandName":"somapacitan","genericName":"somapacitan","approvalYear":"2020","relationship":"same-class"},{"drugId":"somatrogon","brandName":"somatrogon","genericName":"somatrogon","approvalYear":"2023","relationship":"same-class"},{"drugId":"lonapegsomatropin","brandName":"lonapegsomatropin","genericName":"lonapegsomatropin","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00921609","phase":"","title":"Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2006-06","conditions":["Acromegaly"],"enrollment":20,"completionDate":"2025-07"},{"nctId":"NCT07037420","phase":"PHASE2","title":"ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-10-28","conditions":["Acromegaly"],"enrollment":60,"completionDate":"2027-11-11"},{"nctId":"NCT07481734","phase":"PHASE2","title":"Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-02","conditions":["Metabolic Associated Steatotic Liver Disease","Nonalcoholic Steatohepatitis","Hepatic Steatosis"],"enrollment":120,"completionDate":"2028-02-17"},{"nctId":"NCT00647478","phase":"","title":"System-IGF-1 Pathway and Alzheimer's Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2007-10","conditions":["Alzheimer's Disease","Mild Cognitive Impairment","Cognitive Function 1, Social","Control With Normal Activities of Daily Living"],"enrollment":693,"completionDate":"2012-07"},{"nctId":"NCT06930625","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs","status":"RECRUITING","sponsor":"Debiopharm International SA","startDate":"2025-11-26","conditions":["Acromegaly"],"enrollment":119,"completionDate":"2029-03"},{"nctId":"NCT06384547","phase":"PHASE3","title":"A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)","status":"COMPLETED","sponsor":"Viridian Therapeutics, Inc.","startDate":"2024-05-23","conditions":["Thyroid Eye Disease"],"enrollment":231,"completionDate":"2026-01-19"},{"nctId":"NCT07407101","phase":"NA","title":"Impact of Filtration on Autologous Serum Eye Drops","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Limoges","startDate":"2026-04-30","conditions":["Dry Eye Syndrome (DES)"],"enrollment":10,"completionDate":"2027-04-29"},{"nctId":"NCT07173036","phase":"NA","title":"Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under rhGH or LAGH With Stratification According to IGF-1 Levels","status":"NOT_YET_RECRUITING","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2026-03-01","conditions":["Growth Hormone Deficiency"],"enrollment":300,"completionDate":"2031-09-01"},{"nctId":"NCT03253263","phase":"PHASE2","title":"A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants","status":"RECRUITING","sponsor":"OHB Neonatology Ltd.","startDate":"2019-05-09","conditions":["Bronchopulmonary Dysplasia","Chronic Lung Disease of Prematurity","Intraventricular Hemorrhage","Retinopathy of Prematurity (ROP)"],"enrollment":338,"completionDate":"2028-01-21"},{"nctId":"NCT05253287","phase":"PHASE2,PHASE3","title":"Growth Hormone in Decompensated Liver Cirrhosis","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2022-02-01","conditions":["Liver Cirrhosis","Fibrosis","End Stage Liver Disease","Digestive System Disease","Physiological Effect of Drugs","Growth Hormone Treatment","Sarcopenia"],"enrollment":96,"completionDate":"2024-12-31"},{"nctId":"NCT07271212","phase":"NA","title":"Scalp Care Efficacy Evaluation for Premium Revitalizing Elixir","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hungkuang University","startDate":"2025-11-01","conditions":["Scalp Health","Hair Condition","Hair Loss","Alopecia","Sebum Production","Hair Health","Hair Thinning"],"enrollment":60,"completionDate":"2026-05"},{"nctId":"NCT07271199","phase":"NA","title":"Eyelash Effect Evaluation for Premium Rejuvenation Eyelash Serum","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hungkuang University","startDate":"2025-11-01","conditions":["Skin Condition","Eyelash Growth","Eyelashes","Skin Health","Hair Health"],"enrollment":30,"completionDate":"2026-05"},{"nctId":"NCT00803179","phase":"PHASE1","title":"Growth Hormone Therapy for Wasting in Cystic Fibrosis","status":"TERMINATED","sponsor":"University of Massachusetts, Worcester","startDate":"2008-11","conditions":["Cystic Fibrosis"],"enrollment":5,"completionDate":"2012-03"},{"nctId":"NCT00597480","phase":"PHASE4","title":"Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH)","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-01","conditions":["Small for Gestational Age"],"enrollment":10,"completionDate":"2012-01"},{"nctId":"NCT06021054","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)","status":"COMPLETED","sponsor":"Viridian Therapeutics, Inc.","startDate":"2023-11-14","conditions":["Thyroid Eye Disease"],"enrollment":188,"completionDate":"2025-07-25"},{"nctId":"NCT03830775","phase":"NA","title":"A Prospective Randomized Double Blinded Controlled Trial of Non-Operative Management of TFCC Injuries","status":"WITHDRAWN","sponsor":"Edna Rath","startDate":"2020-10-02","conditions":["Wrist Injuries","PRP"],"enrollment":0,"completionDate":"2023-12-31"},{"nctId":"NCT07151807","phase":"","title":"Serum IGF-1 and IGF-1Ec in Malignancy Assessment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Çanakkale Onsekiz Mart University","startDate":"2025-04-01","conditions":["Cancer","Solid Tumor Malignancies","IGF1R","Solid Cancers"],"enrollment":100,"completionDate":"2026-12"},{"nctId":"NCT05645211","phase":"","title":"The AgRP and GH/IGF-1 Axis in Children","status":"NOT_YET_RECRUITING","sponsor":"Columbia University","startDate":"2026-06-10","conditions":["Growth Hormone Deficiency"],"enrollment":156,"completionDate":"2027-12-31"},{"nctId":"NCT06985121","phase":"NA","title":"Scalp Care Efficacy Evaluation for Premium Scalp Revitalizing Essence","status":"COMPLETED","sponsor":"Hungkuang University","startDate":"2025-04-08","conditions":["Scalp Health","Hair Condition","Hair Loss","Sebum Production","Hair and Scalp Health"],"enrollment":60,"completionDate":"2025-07-31"},{"nctId":"NCT03255694","phase":"PHASE2","title":"A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2017-05-12","conditions":["Dwarfism"],"enrollment":360,"completionDate":"2030-06"},{"nctId":"NCT05355272","phase":"PHASE2","title":"Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2024-03-11","conditions":["Gulf War Syndrome","Adult Growth Hormone Deficiency"],"enrollment":20,"completionDate":"2026-07"},{"nctId":"NCT05293366","phase":"","title":"LOng COvid COmorbidities: Endocrine,Metabolic,Neuropsychiatric,Muscle,Cardiovascular,Pulmonary,Dermatologic Dysfunctions","status":"RECRUITING","sponsor":"Federico II University","startDate":"2022-01-27","conditions":["Long Covid-19"],"enrollment":100,"completionDate":"2027-01-27"},{"nctId":"NCT05964712","phase":"","title":"Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study","status":"RECRUITING","sponsor":"Istituto Auxologico Italiano","startDate":"2019-06-18","conditions":["Acromegaly"],"enrollment":30,"completionDate":"2025-12-31"},{"nctId":"NCT05176639","phase":"PHASE3","title":"A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE )","status":"COMPLETED","sponsor":"Viridian Therapeutics, Inc.","startDate":"2021-12-03","conditions":["Thyroid Eye Disease"],"enrollment":113,"completionDate":"2025-03-27"},{"nctId":"NCT05382637","phase":"PHASE2","title":"Growth Hormone in a Patient With a Dominant-Negative GHR Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's National Research Institute","startDate":"2022-08-26","conditions":["Growth Disorders"],"enrollment":1,"completionDate":"2028-09-01"},{"nctId":"NCT07043504","phase":"","title":"Study on Dynamic Changes of Serum IGF-1 Post-Cerebral Hemorrhage and Its Prognostic Correlation","status":"NOT_YET_RECRUITING","sponsor":"Shengjing Hospital","startDate":"2025-07-01","conditions":["Insulin-Like Growth Factor I"],"enrollment":100,"completionDate":"2026-12-31"},{"nctId":"NCT07015554","phase":"","title":"Serum IGF1 on Female HFpEF Patients","status":"ENROLLING_BY_INVITATION","sponsor":"The University of Hong Kong-Shenzhen Hospital","startDate":"2025-01-01","conditions":["HFpEF - Heart Failure With Preserved Ejection Fraction"],"enrollment":120,"completionDate":"2026-12-31"},{"nctId":"NCT02375620","phase":"PHASE2","title":"Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2015-04-23","conditions":["Short Stature Children Born Small for Gestational Age (SGA)"],"enrollment":96,"completionDate":"2025-12"},{"nctId":"NCT06564753","phase":"PHASE2","title":"Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition","status":"COMPLETED","sponsor":"Biomed Industries, Inc.","startDate":"2024-07-19","conditions":["Weight Loss","Obesity","Body Weight","Body Weight Changes"],"enrollment":126,"completionDate":"2025-04-18"},{"nctId":"NCT04730622","phase":"","title":"Study of Parameters of Osteosarcopenia in Patients With Hip Fracture","status":"RECRUITING","sponsor":"Istituto Ortopedico Rizzoli","startDate":"2020-11-23","conditions":["Osteoporotic Fracture of Femur","Osteoarthritis, Hip"],"enrollment":100,"completionDate":"2025-12-31"},{"nctId":"NCT05187377","phase":"PHASE2","title":"A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2022-01-19","conditions":["Phelan-McDermid Syndrome","Autism Spectrum Disorder (ASD)"],"enrollment":32,"completionDate":"2025-02-05"},{"nctId":"NCT04202094","phase":"NA","title":"Fertility in Young Adults Who Did (Not) Store Testicular Tissue Before a Treatment Leading to Fertility Problems","status":"ENROLLING_BY_INVITATION","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2020-09-08","conditions":["Childhood Cancer","Hematological Disorders"],"enrollment":50,"completionDate":"2030-12"},{"nctId":"NCT04697264","phase":"","title":"Adipocytokines in Endometrial Cancer","status":"COMPLETED","sponsor":"University of Surrey","startDate":"2021-04-12","conditions":["Endometrial Cancer","Obesity"],"enrollment":100,"completionDate":"2023-10-31"},{"nctId":"NCT02583763","phase":"","title":"Cardiac Displacement From Third Trimester to Early Childhood","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Linkoeping","startDate":"2013-01","conditions":["IUGR","Fetal Growth Retardation","Intrauterine Growth Restriction"],"enrollment":61,"completionDate":"2027-12"},{"nctId":"NCT06869486","phase":"","title":"Insomnia´s Impact on DNA Stability, Cardio-metabolic Health and Lifestyle Behaviors","status":"RECRUITING","sponsor":"Universidad Autonoma de Baja California","startDate":"2024-10-01","conditions":["Insomnia","Cardiorespiratory Fitness","Metabolic Disease"],"enrollment":300,"completionDate":"2026-12-31"},{"nctId":"NCT06850532","phase":"NA","title":"NMES Effects on Substrate Metabolism and IGF-1","status":"COMPLETED","sponsor":"Mersin University","startDate":"2017-03-17","conditions":["The Effects of Neuromuscular Electrical Stimulation on Exercise Performance"],"enrollment":24,"completionDate":"2019-02-13"},{"nctId":"NCT05558384","phase":"NA","title":"Influence of Adiposity on IGF-1 and Fitness Response to Exercise in Cancer Survivors","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2023-03-22","conditions":["Cancer","Overweight and Obesity"],"enrollment":12,"completionDate":"2024-10-01"},{"nctId":"NCT03932162","phase":"EARLY_PHASE1","title":"Gene Expression Changes In Young and Geriatric Skin","status":"RECRUITING","sponsor":"Wright State University","startDate":"2019-09-06","conditions":["UVB Phototherapy Burn","Insulin-like Growth Factor 1","Aging"],"enrollment":24,"completionDate":"2025-12"},{"nctId":"NCT05869383","phase":"PHASE2,PHASE3","title":"Effect Of Ophiochepalus Striatus Extract On Serum IGF-1 And IL-6 Levels In Elderly Patients With Sarcopenia","status":"COMPLETED","sponsor":"Universitas Sriwijaya","startDate":"2023-05-01","conditions":["Sarcopenia","Geriatric","Muscle Mass","Muscle Strength","Physical Performance"],"enrollment":80,"completionDate":"2023-10-30"},{"nctId":"NCT06522074","phase":"","title":"Evaluating the Role of IGF-1 and S-Klotho In Plaque Phenotype and Vulnerability: the VISION Study.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-10-15","conditions":["Ischemic Heart Disease","Chronic Coronary Syndrome","Optical Coherence Tomography (OCT)"],"enrollment":150,"completionDate":"2026-12-31"},{"nctId":"NCT04531410","phase":"NA","title":"NETwork of Linoleic Acid Supplementation in Cystic Fibrosis","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2021-10-25","conditions":["Cystic Fibrosis"],"enrollment":50,"completionDate":"2024-11-05"},{"nctId":"NCT02431676","phase":"PHASE2","title":"Survivorship Promotion In Reducing IGF-1 Trial","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-05","conditions":["Breast Cancer","Prostate Cancer","Lung Cancer","Colon Cancer","Melanoma of Skin","Endometrial Cancer","Liver Cancer","Pancreatic Cancer","Rectal Cancer","Kidney Cancer","Other Solid Malignant Tumors"],"enrollment":121,"completionDate":"2018-12"},{"nctId":"NCT01424241","phase":"PHASE4","title":"Effects of Sandostatin LAR® in Acromegaly","status":"COMPLETED","sponsor":"Columbia University","startDate":"2006-10","conditions":["Acromegaly"],"enrollment":21,"completionDate":"2014-01"},{"nctId":"NCT00684957","phase":"PHASE1,PHASE2","title":"Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors","status":"TERMINATED","sponsor":"Columbia University","startDate":"2008-01","conditions":["Growth Hormone Deficiency"],"enrollment":5,"completionDate":"2012-10"},{"nctId":"NCT04054505","phase":"NA","title":"Effectiveness of a Nutraceutical in Raising Circulating Serum Vitamin, Mineral and Amino Acid Levels in Patients.","status":"COMPLETED","sponsor":"Optimal Health Research","startDate":"2019-01-02","conditions":["Vitamin Deficiency"],"enrollment":275,"completionDate":"2021-01-04"},{"nctId":"NCT06456645","phase":"","title":"Effects of Smoking on Placenta and Lactation","status":"COMPLETED","sponsor":"Celal Bayar University","startDate":"2017-05-01","conditions":["Smoking, Tobacco","Placenta Diseases","Breastfeeding","Fetal Conditions"],"enrollment":70,"completionDate":"2019-11-05"},{"nctId":"NCT06426524","phase":"NA","title":"Efficacy of Insulin Like Growth Factor-1(IGF-1) on Bone Regeneration in Intrabony Defects : A Clinico-radiograph Study","status":"RECRUITING","sponsor":"Dr R Viswa Chandra","startDate":"2023-05-19","conditions":["Intrabony Periodontal Defect"],"enrollment":24,"completionDate":"2024-05"},{"nctId":"NCT04003207","phase":"PHASE2","title":"Growth Hormone Treatment in Children With Phelan McDermid Syndrome","status":"COMPLETED","sponsor":"Swathi Sethuram","startDate":"2019-09-13","conditions":["Phelan McDermid Syndrome"],"enrollment":6,"completionDate":"2020-06-05"},{"nctId":"NCT06094998","phase":"","title":"Health Status of Children Born After Assisted Reproductive Technologies","status":"COMPLETED","sponsor":"Kazakhstan's Medical University \"KSPH\"","startDate":"2023-10-18","conditions":["Children Born After Assisted Reproductive Technologies","Health Status","Child Development"],"enrollment":252,"completionDate":"2024-01-22"},{"nctId":"NCT02636270","phase":"PHASE1,PHASE2","title":"IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2015-12-21","conditions":["Short Stature"],"enrollment":7,"completionDate":"2022-12-01"},{"nctId":"NCT06275373","phase":"","title":"The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction","status":"RECRUITING","sponsor":"Walter Reed National Military Medical Center","startDate":"2021-05-12","conditions":["Thyroid Eye Disease","Graves Ophthalmopathy","Graves Disease"],"enrollment":100,"completionDate":"2027-12-12"},{"nctId":"NCT01970345","phase":"PHASE2","title":"A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder","status":"TERMINATED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2014-05","conditions":["Autism Spectrum Disorder"],"enrollment":3,"completionDate":"2017-09-13"},{"nctId":"NCT05812079","phase":"","title":"Insulin Like Growth Factor-1 Against Oxidative Stress in Vitiligo","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2024-02-01","conditions":["Vitiligo"],"enrollment":33,"completionDate":"2024-10-01"},{"nctId":"NCT06114550","phase":"NA","title":"Resistance Training on Growth Factors","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2024-02-27","conditions":["Cognitive Function"],"enrollment":12,"completionDate":"2024-04-07"},{"nctId":"NCT05612802","phase":"NA","title":"A New Marker for Early Diagnosis of Pneumoperitoneum-Related Acute Kidney Injury: Insulin-Like Growth Factor-1 (IGF-1)","status":"COMPLETED","sponsor":"Baskent University","startDate":"2023-02-08","conditions":["Acute Kidney Injury (Nontraumatic)","Pneumoperitoneum"],"enrollment":25,"completionDate":"2023-05-30"},{"nctId":"NCT05301569","phase":"","title":"Relation Between Serum IGF-1 & BMI In Acne Vulgaris","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-04-01","conditions":["Evaluation of Serum Level of Insulin Like Growth Factor 1"],"enrollment":90,"completionDate":"2024-05-30"},{"nctId":"NCT04349839","phase":"","title":"ACRODAT Prospective Evaluation Study","status":"UNKNOWN","sponsor":"University of Aarhus","startDate":"2020-01-15","conditions":["Acromegaly"],"enrollment":500,"completionDate":"2025-02-01"},{"nctId":"NCT06071403","phase":"","title":"The Effects of Time Points to Cease Parenteral Nutrition and IGF-1 on Very Low Birth Weight Infants","status":"RECRUITING","sponsor":"Peking University","startDate":"2023-07-01","conditions":["Growth Retardation"],"enrollment":416,"completionDate":"2026-09-30"},{"nctId":"NCT06014398","phase":"NA","title":"Improving Survivorship and Health-related Quality of Life in Patients With Primary Brain Tumours","status":"UNKNOWN","sponsor":"Royal College of Surgeons, Ireland","startDate":"2023-09-01","conditions":["Hypopituitarism","Radiotherapy-Induced Hypopituitarism","Brain Tumor"],"enrollment":50,"completionDate":"2025-09-01"},{"nctId":"NCT00673309","phase":"PHASE2,PHASE3","title":"Assessment of Mechanisms of Improved Wound Healing","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2000-07","conditions":["Burns"],"enrollment":644,"completionDate":"2013-04"},{"nctId":"NCT05333133","phase":"NA","title":"High Calorie Formula Intervention on Weight, Length Increment, Total Lymphocyte Counts, TNF-alpha and IGF-1 in Failure to Thrive Children","status":"COMPLETED","sponsor":"Universitas Airlangga","startDate":"2021-10-04","conditions":["Failure to Thrive","Infection, Bacterial","Growth Faltering"],"enrollment":80,"completionDate":"2022-12-30"},{"nctId":"NCT01721577","phase":"PHASE1,PHASE2","title":"Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2012-12","conditions":["Glioblastoma","Gliosarcoma","Anaplastic Astrocytoma","Anaplastic Oligodendroglioma","Anaplastic Oligoastrocytoma","Anaplastic Ependymoma"],"enrollment":10,"completionDate":"2015-12"},{"nctId":"NCT03420144","phase":"PHASE2,PHASE3","title":"Growth Hormone Therapy in Liver Cirrhosis","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2018-01-15","conditions":["Cirrhosis, Liver"],"enrollment":76,"completionDate":"2020-06-30"},{"nctId":"NCT05144035","phase":"PHASE4","title":"A Real World Study of the Effect of Early PEG-rhGH Therapy on Cognitive Development of SGA Infants","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2022-04-06","conditions":["Small for Gestational Age Infant","Growth Hormone Treatment","Cognitive Developmental Disorder"],"enrollment":138,"completionDate":"2026-06-30"},{"nctId":"NCT00572156","phase":"PHASE2","title":"rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency","status":"TERMINATED","sponsor":"Ipsen","startDate":"2007-12","conditions":["Insulin-like Growth Factor-1 Deficiency"],"enrollment":106,"completionDate":"2012-03"},{"nctId":"NCT05788822","phase":"NA","title":"MVA to Improve the Pregnancy Outcome in Aged Infertility Women With Assisted Reproductive Technology","status":"UNKNOWN","sponsor":"Nanjing University","startDate":"2022-10-08","conditions":["Infertility, Female","IVF","Reproductive Disorder","Oocyte"],"enrollment":148,"completionDate":"2025-12"},{"nctId":"NCT05004389","phase":"","title":"Biomarkers of Independent Walking Post-Stroke","status":"UNKNOWN","sponsor":"University of Vermont","startDate":"2021-12-02","conditions":["Stroke, Acute","Gait, Hemiplegic"],"enrollment":35,"completionDate":"2023-05"},{"nctId":"NCT05750303","phase":"","title":"Potential Prognostic Markers of Recovery in Post-stroke Rehabilitation","status":"COMPLETED","sponsor":"Medical University of Lodz","startDate":"2022-01-02","conditions":["Ischemic Stroke"],"enrollment":32,"completionDate":"2023-01-31"},{"nctId":"NCT04143204","phase":"","title":"Nutrition and Growth in Very Preterm Infants","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2019-08-01","conditions":["Premature","Growth"],"enrollment":180,"completionDate":"2022-10-31"},{"nctId":"NCT05038306","phase":"PHASE2","title":"Chinese Medicine WT for Spinocerebellar Ataxia Type 3","status":"COMPLETED","sponsor":"Changhua Christian Hospital","startDate":"2021-05-31","conditions":["Ataxia, Spinocerebellar","Insulin-Like Growth Factor I","Medicine, Chinese Traditional"],"enrollment":33,"completionDate":"2022-09-26"},{"nctId":"NCT02152124","phase":"","title":"Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2014-06-01","conditions":["Acromegaly"],"enrollment":21,"completionDate":"2017-08-31"},{"nctId":"NCT04021017","phase":"PHASE1","title":"PRE-GAiN Bone Health Pilot Study","status":"WITHDRAWN","sponsor":"University of Saskatchewan","startDate":"2020-01-21","conditions":["Anorexia Nervosa"],"enrollment":0,"completionDate":"2022-12-13"},{"nctId":"NCT05642169","phase":"NA","title":"Effect of a HIIT Program on Quality of Life, Executive Functions, and IGF-1 Response in Sedentary Young University Women","status":"UNKNOWN","sponsor":"University of Seville","startDate":"2022-10-15","conditions":["Insulin Growth Factor I Deficiency","IGF1 Deficiency","Executive Function Disorder"],"enrollment":75,"completionDate":"2023-04-15"},{"nctId":"NCT02217345","phase":"PHASE2","title":"Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-06-02","conditions":["Nonalcoholic Fatty Liver Disease (NAFLD)"],"enrollment":131,"completionDate":"2021-09-13"},{"nctId":"NCT02726542","phase":"EARLY_PHASE1","title":"Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-05-03","conditions":["NAFLD"],"enrollment":24,"completionDate":"2020-04-02"},{"nctId":"NCT05529550","phase":"","title":"Assessment of Nutritional Status and Role of Insulin-like Growth Factor-1 in Children","status":"COMPLETED","sponsor":"Menoufia University","startDate":"2020-10-01","conditions":["Thalassemia"],"enrollment":102,"completionDate":"2021-12-01"},{"nctId":"NCT03610412","phase":"PHASE3","title":"Cinnamomum Cassia Effect on IGF1 and Metabolic Control in Patients With DM2 Without Glycemic Control Metformin Treated","status":"COMPLETED","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2019-08-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":28,"completionDate":"2021-08-18"},{"nctId":"NCT05390073","phase":"","title":"Growth Hormone in EB","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2022-05-25","conditions":["Epidermolysis Bullosa Dystrophica"],"enrollment":50,"completionDate":"2022-06-15"},{"nctId":"NCT02386839","phase":"PHASE2","title":"Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)","status":"COMPLETED","sponsor":"Shire","startDate":"2015-03-26","conditions":["Retinopathy of Prematurity (ROP)"],"enrollment":76,"completionDate":"2021-09-28"},{"nctId":"NCT01525901","phase":"PHASE2","title":"Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2012-02","conditions":["22q13 Deletion Syndrome","Phelan-McDermid Syndrome"],"enrollment":19,"completionDate":"2016-08-23"},{"nctId":"NCT03041701","phase":"PHASE1,PHASE2","title":"Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-07-07","conditions":["Rhabdomyosarcoma","Rhabdomyosarcoma, Alveolar","Rhabdomyosarcoma, Embryonal"],"enrollment":14,"completionDate":"2021-10-16"},{"nctId":"NCT02410343","phase":"PHASE3","title":"Study of TV-1106 in Growth Hormone-Deficient Adults","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-04-30","conditions":["Growth Hormone Deficiency"],"enrollment":14,"completionDate":"2015-12-31"},{"nctId":"NCT00577577","phase":"PHASE2","title":"Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2007-12","conditions":["Myotonic Dystrophy Type 1"],"enrollment":69,"completionDate":"2008-12-29"},{"nctId":"NCT01811576","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-03-31","conditions":["Growth Hormone Deficiency"],"enrollment":52,"completionDate":"2013-08-05"},{"nctId":"NCT02952885","phase":"PHASE3","title":"Strict IGF-1 Control in Acromegaly","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2017-07-27","conditions":["Acromegaly"],"enrollment":10,"completionDate":"2020-05-07"},{"nctId":"NCT00516386","phase":"PHASE1,PHASE2","title":"Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2007-03","conditions":["Anorexia Nervosa"],"enrollment":16,"completionDate":"2008-12"},{"nctId":"NCT05100550","phase":"NA","title":"Family-based Health Education Program and Zinc Supplementation for Stunted Mother","status":"UNKNOWN","sponsor":"Hasanuddin University","startDate":"2020-09-01","conditions":["Stunting","Maternal-Fetal Relations"],"enrollment":126,"completionDate":"2021-12-01"},{"nctId":"NCT00171730","phase":"PHASE2","title":"An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-08-24","conditions":["Acromegaly"],"enrollment":30,"completionDate":"2013-12-06"},{"nctId":"NCT03384719","phase":"NA","title":"The Effect of Milk Protein vs Blends of Milk and Plant Protein on Growth Markers in 7-8 Year Old Healthy Danish Children","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2018-01-18","conditions":["Growth Acceleration","Growth; Stunting, Nutritional"],"enrollment":129,"completionDate":"2018-12-18"},{"nctId":"NCT04123782","phase":"NA","title":"Focused Shockwave Treatment in the Recovery Process of Acute Muscle Injuries in Soccer Players","status":"COMPLETED","sponsor":"Fundación Garcia Cugat","startDate":"2019-06-29","conditions":["Muscle Injury"],"enrollment":60,"completionDate":"2021-07-15"},{"nctId":"NCT01301183","phase":"PHASE3","title":"Effects of Anorexia Nervosa on Peak Bone Mass","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2011-02","conditions":["Anorexia Nervosa"],"enrollment":75,"completionDate":"2020-03"},{"nctId":"NCT03225040","phase":"","title":"Bone MicroArchitecture in Acromegaly","status":"COMPLETED","sponsor":"Columbia University","startDate":"2016-08-03","conditions":["Acromegaly","Osteoporosis Risk"],"enrollment":77,"completionDate":"2019-12-21"},{"nctId":"NCT01096784","phase":"PHASE2","title":"IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity","status":"COMPLETED","sponsor":"Shire","startDate":"2010-06-18","conditions":["Retinopathy of Prematurity (ROP)"],"enrollment":121,"completionDate":"2016-03-30"},{"nctId":"NCT04860037","phase":"","title":"Micromegaly and Discrepancy Between Growth Hormone and IGF1 at the Diagnosis and Follow-up of Acromegalic Patients","status":"UNKNOWN","sponsor":"University Hospital, Montpellier","startDate":"2010-01-01","conditions":["Acromegaly"],"enrollment":250,"completionDate":"2022-12-01"},{"nctId":"NCT03616509","phase":"PHASE4","title":"GH in Adults With PWS, Effect on Hypotonia Evaluated by Functional MRI, Relationship With Strength and Body Composition","status":"COMPLETED","sponsor":"Corporacion Parc Tauli","startDate":"2017-06-19","conditions":["Prader-Willi Syndrome"],"enrollment":30,"completionDate":"2019-07-26"},{"nctId":"NCT01207908","phase":"PHASE1,PHASE2","title":"Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2010-11","conditions":["Duchenne Muscular Dystrophy"],"enrollment":44,"completionDate":"2013-06"},{"nctId":"NCT04710745","phase":"","title":"Atrial Fibrillation in Relationship to Plasma Biomarkers","status":"UNKNOWN","sponsor":"Premedix Academy","startDate":"2020-12-04","conditions":["Atrial Fibrillation"],"enrollment":300,"completionDate":"2024-12"},{"nctId":"NCT04710186","phase":"","title":"AR, IGF-IR, IR and Peripheral Artery Disease","status":"UNKNOWN","sponsor":"University of Catanzaro","startDate":"2018-08-01","conditions":["Androgen Receptor Abnormal","Insulin-Like Growth Factor I Deficiency","Insulin Receptor, Defect in"],"enrollment":30,"completionDate":"2021-03-01"},{"nctId":"NCT00846872","phase":"PHASE1,PHASE2","title":"Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance","status":"WITHDRAWN","sponsor":"Tulane University Health Sciences Center","startDate":"2008-07","conditions":["Insulin Resistance","Endothelial Dysfunction"],"enrollment":0,"completionDate":"2012-03"},{"nctId":"NCT00510315","phase":"","title":"Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-07","conditions":["Leukemia","Hodgkin's Lymphoma","Non-Hodgkin's Lymphoma","Myelodysplastic Syndrome"],"enrollment":11,"completionDate":"2016-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"MMSL":"20793","NDDF":"011373","UNII":"NZ8M50KKRG","VANDF":"4025086","INN_ID":"8437","RXNORM":"616877","UMLSCUI":"C1696547","chemblId":"CHEMBL1201717","ChEMBL_ID":"CHEMBL1201717","KEGG_DRUG":"D04870","DRUGBANK_ID":"DB14751","SNOMEDCT_US":"422284004"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2005-","companyName":"Insmed","relationship":"Original Developer"}],"publicationCount":13,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"H01AC05","allCodes":["H01AC05"]},"biosimilarFilings":[],"originalDeveloper":"Insmed","recentPublications":[{"date":"2022 May","pmid":"34717953","title":"Development of Protein-Specific Analytical Methodologies to Evaluate Compatibility of Recombinant Human (rh)IGF-1/rhIGFBP-3 with Intravenous Medications Co-Administered to Neonates.","journal":"Journal of pharmaceutical sciences"},{"date":"2015 Feb 15","pmid":"25541285","title":"The insulin-like growth factor I system: physiological and pathophysiological implication in cardiovascular diseases associated with metabolic syndrome.","journal":"Biochemical pharmacology"},{"date":"2012 Dec 6","pmid":"22952056","title":"Insulinlike growth factor (IGF)-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy.","journal":"Molecular medicine (Cambridge, Mass.)"},{"date":"2010 Nov","pmid":"21225019","title":"Gateways to clinical trials.","journal":"Methods and findings in experimental and clinical pharmacology"},{"date":"2009","pmid":"19627167","title":"Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.","journal":"BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","brandName":"MECASERMIN RINFABATE","companyName":"Insmed","companyId":"insmed","modality":"Recombinant protein","firstApprovalDate":"2005","aiSummary":"","enrichmentLevel":3,"visitCount":2,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2005-12-12T00:00:00.000Z","mah":"INSMED","brand_name_local":null,"application_number":""},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2005-12-12T00:00:00.000Z","mah":"INSMED","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2005-12-12T00:00:00.000Z","mah":"INSMED","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2005-12-12T00:00:00.000Z","mah":"INSMED","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2005-12-12T00:00:00.000Z","mah":"INSMED","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2005-12-12T00:00:00.000Z","mah":"INSMED","brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"application withdrawn","approval_date":null,"mah":null,"brand_name_local":"Iplex","application_number":"EMEA/H/C/000754"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Iplex","application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:23:05.585871+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}